Institution
Lankenau Medical Center
Healthcare•Philadelphia, Pennsylvania, United States•
About: Lankenau Medical Center is a healthcare organization based out in Philadelphia, Pennsylvania, United States. It is known for research contribution in the topics: Atrial fibrillation & Medicine. The organization has 436 authors who have published 414 publications receiving 7095 citations. The organization is also known as: Lankenau Hospital.
Topics: Atrial fibrillation, Medicine, Cancer, Warfarin, Stroke
Papers
More filters
••
TL;DR: Women with ASCVD were more likely to report poorer patient experience, lower health‐related quality of life, and poorer perception of their health when compared with men, which have important public health implications.
Abstract: Background Atherosclerotic cardiovascular disease (ASCVD) accounts for approximately one third of deaths in women. Although there is an established relationship between positive patient experiences...
61 citations
••
TL;DR: Ina-L blockade with mexiletine may be an effective treatment approach to terminate refractory TdP from several acquired causes of LQTS.
59 citations
••
University of Toronto1, Cedars-Sinai Medical Center2, NewYork–Presbyterian Hospital3, Rutgers University4, Cleveland Clinic5, Northwestern University6, University of Missouri–Kansas City7, St. Paul's Hospital8, New York University9, University of Washington10, Scott & White Hospital11, Emory University12, Lankenau Medical Center13, University of Pennsylvania14, Morristown Medical Center15, Edwards Lifesciences Corporation16
TL;DR: In patients with severe aortic stenosis and low surgical risk, TAVR with the SAPIEN 3 valve was associated with similar percentage of moderate or severe AR compared with SAVR but higher percentage of mild AR, and high Zva and low tricuspid annulus plane systolic excursion were associated with worse outcome at 1 year whereas AR and severe prosthesis–patient mismatch were not.
Abstract: Background: This study aimed to compare echocardiographic findings in low-risk patients with severe aortic stenosis after surgical aortic valve replacement (SAVR) or transcatheter aortic valve repl...
59 citations
••
TL;DR: In this paper, the potential of nanoparticles to modulate biological effects independently of any engineered function is discussed, and how these effects might be relevant for nanomedicine design and functional considerations.
Abstract: Nanoparticles are often engineered as a scaffolding system to combine targeting, imaging and/or therapeutic moieties into a unitary agent. However, mostly overlooked, the nanomaterial itself interacts with biological systems exclusive of application-specific particle functionalization. This nanoparticle biointerface has been found to elicit specific biological effects, which we term ‘ancillary effects’. In this Review, we describe the current state of knowledge of nanobiology gleaned from existing studies of ancillary effects with the objectives to describe the potential of nanoparticles to modulate biological effects independently of any engineered function; evaluate how these effects might be relevant for nanomedicine design and functional considerations, particularly how they might be useful to inform clinical decision-making; identify potential clinical harm that arises from adverse nanoparticle interactions with biology; and, finally, highlight the current lack of knowledge in this area as both a barrier and an incentive to the further development of nanomedicine. Nanoparticles used for biomedical applications might elicit unexpected adverse or beneficial biological effects unrelated to the function for which they were designed. In this Review, the authors describe some of these ‘yin and yang’ ancillary effects, and discuss their implications for nanomedicine development.
58 citations
••
TL;DR: Antithrombotic therapy, rates of cerebrovascular accident, other thrombosis events and cardiac death were similar in AF patients with or without a history of cancer, however, patients with cancer were at higher risk of major bleeding and non-CV death.
Abstract: Aims The presence of cancer can complicate treatment choices for patients with atrial fibrillation (AF) increasing both the risk of thrombotic and bleeding events. Methods and results Using data from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation, we aimed to characterize AF patients with cancer, to describe their management and to assess the association between cancer and cardiovascular (CV) outcomes. Among 9749 patients, 23.8% had history of cancer (57% solid malignancy, 1.3% leukaemia, 3.3% lymphoma, 40% other type, and 2.2% metastatic cancer). Patients with history of cancer were older, more likely to have CV disease, CV risk factors, and prior gastrointestinal bleeding. No difference in antiarrhythmic and antithrombotic therapy was observed between those with and without cancer. Patients with history of cancer had a significantly higher risk of death (7.8 vs. 4.9 deaths per 100 patient-years follow-up, P = 0.0003) mainly driven by non-CV death (4.2 vs. 2.4 per 100 patient-years follow-up; P = 0.0004) and higher risk of major bleeding (5.1 vs. 3.5 per 100 patient-years follow-up; P = 0.02) compared with non-cancer patients; no differences were observed in risks of strokes/non-central nervous system embolism (1.96 vs. 1.48, P = 0.74) and CV death (2.89 vs. 2.07, P = 0.35) between the two groups. Conclusion A history of cancer is common among AF patients with up to one in four patients having both. Antithrombotic therapy, rates of cerebrovascular accident, other thrombotic events and cardiac death were similar in AF patients with or without a history of cancer. Patients with cancer, however, were at higher risk of major bleeding and non-CV death.
56 citations
Authors
Showing all 440 results
Name | H-index | Papers | Citations |
---|---|---|---|
Abass Alavi | 113 | 1298 | 56672 |
Robert T. Sataloff | 51 | 680 | 10252 |
Flemming Forsberg | 49 | 333 | 9769 |
Michael D. Ezekowitz | 43 | 164 | 16799 |
Gan-Xin Yan | 42 | 105 | 10110 |
William A. Gray | 41 | 135 | 6830 |
Peter D. Le Roux | 36 | 81 | 4522 |
James M. Mullin | 35 | 98 | 4095 |
Georgia Panagopoulos | 32 | 102 | 3250 |
Karen Chiswell | 30 | 132 | 3477 |
Peter R. Kowey | 29 | 113 | 3083 |
Tracey L. Evans | 29 | 97 | 4465 |
Pietro Delise | 27 | 103 | 5080 |
Caleb B. Kallen | 24 | 44 | 3517 |
Louis E. Samuels | 23 | 95 | 2380 |